Dupilumab treatment reduces serum SCCA2 levels in patients with atopic dermatitis

被引：0
|
作者：
Kita, Kanako [1 ]
Imai, Yasutomo [1 ,2 ]
Nagai, Makoto [1 ]
Natsuaki, Masaru [1 ]
Kanazawa, Nobuo [1 ]
机构：
[1] Hyogo Med Univ, Dept Dermatol, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan
[2] Imai Adult & Pediat Dermatol, Osaka, Japan
来源：
JOURNAL OF CUTANEOUS IMMUNOLOGY AND ALLERGY | 2023年 / 6卷 / 03期
基金：
日本学术振兴会;
关键词：
D O I：
10.1002/cia2.12282
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
Dupilumab treatment reduced serum SCCA2 levels in patients with atopic dermatitis. Interestingly, even though the skin eruptions had not yet fully disappeared, serum SCCA2 levels were reduced well to below normal by the administration of dupilumab.
引用
收藏
页码：100 / 101
页数：2
相关论文
共 50 条
  • [31] Long-term dupilumab treatment up to 100 weeks reduces serum biomarkers in adult patients with moderate-to-severe atopic dermatitis
    Beck, L. A.
    Thaci, D.
    Bissonnette, R.
    Deleuran, M.
    Bastian, M.
    Harel, S.
    Chen, Z.
    Levit, N. A.
    Rossi, A. B.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 55 - 56
  • [32] Long-term dupilumab treatment up to 100 weeks reduces serum biomarkers in adult patients with moderate-to-severe atopic dermatitis
    Thaci, D.
    Bissonnette, R.
    Deleuran, M.
    Harel, S.
    Chen, Z.
    Levit, N. A.
    Rossi, A. B.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E122 - E122
  • [33] Polyenthesitis during treatment with dupilumab for atopic dermatitis
    Ishibashi, M.
    Honda, T.
    Tabuchi, Y.
    Kabashima, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (07) : E319 - E321
  • [34] Thrombocytopenia After Dupilumab for the Treatment of Atopic Dermatitis
    Bressan, Aline Lopes
    Troncoso, Natalia Torres
    Sousa, Nathalie Andrade
    DERMATITIS, 2025, 36 (01) : e88 - e89
  • [35] Dupilumab reduces the Frequency of Infection in a Patient with severe atopic Dermatitis
    Kohlmann, J.
    Simon, J-C
    Treudler, R.
    Ziemer, M.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 146 - 147
  • [36] Recognition of atopic keratoconjunctivitis during treatment with dupilumab for atopic dermatitis
    Cheng, Justine
    Jiang, Lai
    Morrow, Nicole C.
    Avdic, Armin
    Fairley, Janet A.
    Ling, Jennifer J.
    Greiner, Mark A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (01) : 265 - 267
  • [37] IgE levels in patients with atopic dermatitis steadily decrease during treatment with dupilumab regardless of dose interval
    Dekkers, Coco
    van der Wal, M. Marlot
    van den Noort, Leonie
    Bakker, Daphne S.
    de Bruin-Weller, Marjolein
    van Wijk, Femke
    CLINICAL AND EXPERIMENTAL ALLERGY, 2023, 53 (11): : 1222 - 1225
  • [38] RESULT OF TREATMENT PATIENTS WITH ATOPIC DERMATITIS - INEFFECTIVENESS DUPILUMAB CASE SERIES
    Sroka-Tomaszewska, Jowita
    Herkowiak, Aleksandra
    Wilkowska, Aleksandra
    Trzeciak, Magdalena
    Nowicki, Roman J.
    ACTA DERMATO-VENEREOLOGICA, 2023, 103 : 33 - 33
  • [39] Psoriasiform Dermatitis After Initiation of Treatment with Dupilumab for Atopic Dermatitis
    Fowler, Emilie
    Silverberg, Jonathan I.
    Fox, Joshua D.
    Yosipovitch, Gil
    DERMATITIS, 2019, 30 (03) : 234 - 236
  • [40] Treatment of Severe Atopic Dermatitis with Dupilumab in Three Patients with Renal Diseases
    Foti, Caterina
    Romita, Paolo
    Ambrogio, Francesca
    Manno, Carlo
    Filotico, Raffaele
    Cassano, Nicoletta
    Vena, Gino Antonio
    De Marco, Aurora
    Cazzato, Gerardo
    Mennuni, Biagina Gisella
    LIFE-BASEL, 2022, 12 (12):
12345